1. October 7, 2022

    PRAC October 2022 – New measures for terlipressin-containing medicines and change to product information for combination of medicines with codeine and ibuprofen

    During its October 2022 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended new measures for terlipressin-containing medicines and has also recommended a change to the product information for codeine with ibuprofen combination medicines. The PRAC also discussed direct healthcare professional communications (DHPCs) containing important safety information for terlipressin-containing medicines and Imbruvica.

    Source: FAMHP

    Read more

  2. October 7, 2022

    Amended legislation: drug precursors added to list of scheduled substances

    The European Commission's new Delegated Regulation (EU) 2022/1518 adds two drug precursors to the list of scheduled substances. The regulation entered into force on 3 October 2022.

    Source: FAMHP

    Read more

  3. October 6, 2022

    IFAPP Today newsletter - October 2022

    Source: IFAPP

    Please find here the link to the IFAPP TODAY newsletter of October 2022.

    Read more

  4. October 3, 2022

    Flash VIG-news : Dispensation of pholcodine-containing medicinal products suspended due to the risk of allergic cross-reactivity with neuromuscular blocking agents

    Due to concerns about the risk of anaphylactic reactions, the dispensation of pholcodine-containing medicinal products is suspended from 1 October 2022.

    Source: FAMHP

    Read more

  5. September 30, 2022

    Limited availability of thrombolytics: recommendations for hospital pharmacists and specialist physicians.

    België wordt net als andere Europese landen geconfronteerd met kritieke beschikbaarheidsproblemen van trombolytica, dat zijn geneesmiddelen om bloedstolsels op te lossen. Het FAGG doet aanbevelingen rond het rationeel gebruik van deze geneesmiddelen en prioritisering van indicaties. De stock binnen de ziekenhuizen wordt opgevolgd en een noodvoorraad zal worden voorzien. 

    À l’instar d’autres pays européens, la Belgique est confrontée à des problèmes de disponibilité critique de thrombolytiques (médicaments servant à dissoudre les caillots sanguins). L’AFMPS formule des recommandations sur l’usage rationnel de ces médicaments et la priorisation d’indications. Le stock hospitalier fait l’objet d’un suivi et un stock d’urgence sera constitué. 

    Source: FAMHP

    Read more

  6. September 29, 2022

    Ozempic: recommendations for doctors (specialists) and (hospital) pharmacists due to limited availability

    There is limited availability of the medicine Ozempic (semaglutide-based solution for subcutaneous injection) due to an acute increase in demand.  This limited availability will certainly last until early 2023.  Experts from the FAMHP's Unavailability Task Force give recommendations. 

    Source: FAMHP

    Read more

  7. September 29, 2022

    Warning against the use of illegal TKTX ointment after applying tattoos

    The FAMHP wants to warn consumers in Belgium not to use TKTX ointment, an illegal pain-relieving cream. It is mainly used to alleviate pain when applying a tattoo, permanent make-up ... TKTX ointment is not licensed in Belgium or Europe and therefore no guarantees can be given with regard to the composition, safety, quality or efficiency of this illegal medicine.

    Source: FAMHP

    Read more

  8. September 15, 2022

    PRAC September 2022 –Reviews of topiramate and pholcodine medicines started

    During the September 2022 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has started a referral of topiramate and also started a referral of pholcodine medicines.

    Source: FAMHP

    Read more

  9. September 12, 2022

    IFAPP Today newsletter - September 2022

    Source: IFAPP

    Please find here the link to the IFAPP TODAY newsletter of September 2022.

    Read more

  10. August 30, 2022

    Coronavirus: overview of side effects COVID-19 vaccines from August 25, 2022

    Het volgende cumulatief overzicht van de bijwerkingen die zijn gemeld na toediening van een COVID-19-vaccin in België zal worden gepubliceerd op 24 november 2022.

    Le prochain aperçu cumulatif des effets indésirables signalés suite à l'administration d'un vaccin contre la COVID-19 en Belgique sera publié le 24 novembre 2022. 

    Source: FAMHP

    Read more